SCHEMBL106292

SCHEMBL106292

NCCCC/C=C/CCCCN

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.54
DNM1 Q05193 7/20 0.50
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA3 P07451 3/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 3/20 0.50
CA5A P35218 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
TSHR P16473 3/20 0.50
LMNA P02545 1/20 0.50
BLM P54132 1/20 0.50
SLC6A5 Q9Y345 2/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL106293 1.00 NFKB1 (0.54) NFKB1DNM1CA12CA1CA2
SCHEMBL4456562 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL7929387 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL4788839 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL23093976 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL23094031 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL10794505 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL23094002 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL10794508 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL23094022 0.93 DNM1 (0.53) NFKB1DNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
EP-4098750-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2022-12-07 EP disclosed
EP-3230463-B1 RAPID PRETREATMENT SWEETWATER ENERGY INC (US) 2022-05-25 EP disclosed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP disclosed
US-20100086981-A1 COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS QTEROS, INC. (US) 2010-04-08 US disclosed
US-20090203089-A1 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-13 US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA NFKB1 4175/4885DNM1 4399/4885CA12 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.